Citations 1
A pilot, randomized, placebo-controlled trial of rimegepant on visceral sensation and symptoms in nonconstipation IBS pain
Halawi, Houssam, Matar, Ayah, Wang, Iris, Jencks, Kara J. , Busciglio, Irene, Eckert, Deborah J., Harmsen, William S., Camilleri, Michael, Wang, Xiao Jing , Matar, Ayah , Matar, Ayah , Wang, Xiao Jing , Eckert, Deborah, Camilleri, M , Jencks, Kara , Halawi, Houssam , Matar, Ayah , Harmsen, William S., Camilleri, Michael
American Journal of Physiology-Gastrointestinal and Liver Physiology | February 4, 2026 | Volume: 330 | Issue: 4 | Pages: G369-G380
This pilot, randomized, double-blind trial in a relatively small sample of patients with IBS-related pain shows rimegepant significantly reduced sensations of gas, urgency, and pain during rectal distention and decreased rectal compliance. Decrease in compliance implies that changes in physical properties or distensibility of rectum did not contribute to alterations in rectal sensation. Same dose of rimegepant did not significantly impact daily abdominal pain, BM frequency, or colonic transit. There were no serious adverse events.